Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway

Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Wenliang, Zhu, Sicong, Cao, Jun, Zhang, Lei, Li, Wenda, Liu, Kairui, Zhong, Jinyi, Shang, Changzhen, Chen, Yajin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841021/
https://www.ncbi.nlm.nih.gov/pubmed/28276313
http://dx.doi.org/10.3727/096504017X14886444100783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841021/
https://www.ncbi.nlm.nih.gov/pubmed/28276313
http://dx.doi.org/10.3727/096504017X14886444100783

Ejemplares similares